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Impact of 3rd generation drugs on the activity of first-line 
chemotherapy in advanced non-small cell lung cancer (NSCLC): a 
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A two-drug platinum-based regimen with cisplatin or carboplatin 
combined with a third-generation agent gemcitabine (G), paclitaxel (P), 
vinorelbine (V), or docetaxel (D) is the standard ﬁrst-line treatment 
for advanced NSCLC patients. Large clinical trials comparing various 
third-generation doublets showed similar efﬁcacy.
The aim of this study is to assess the impact of G, P, V and D on the 
activity of ﬁrst-line chemotherapy in advanced NSCLC, we carried 
out four separate meta-analyses on data from 6,671 NSCLC patients 
who were enrolled in 18 randomized trials comparing a G or P or V or 
D-containing vs. G or P or V or D-free regimens. We constructed 2x2 
tables using response to treatment data. For trials with more than one 
eligible free comparator arm, individual comparisons between the G 
or P or V or D-based treatment arms and each of the comparator arms 
were analyzed. A general variance-based method was used to estimate 
the pooled odds ratio (OR) and 95% conﬁdence interval (CI). We as-
sessed for heterogeneity among the trials based on standard methods.
Seventeen, 9, 14 and 8 comparisons contributed to this analysis for G, 
P, V and D respectively. Comparing G-containing vs. G-free regimens, 
the OR for progression was 0.8633 (CI 95% 0.76-0.97; p=0.016); no 
signiﬁcant difference was observed for overall (complete + partial) 
response (OR 0.96, CI 95% 0.84-1.10). The heterogeneity chi-square 
were 12.97 (p=0.60) and 19.53 (p=0.24), respectively. Comparing 
P-containing vs. P-free regimens, no signiﬁcant difference was ob-
served for overall response (OR 0.96, CI 95% 0.83-1.11) while P was 
estimated to be associated to an increased risk of progression (OR 1.21, 
CI 95% 1.06-1.38; p=0.0045). The heterogeneity chi-square were 5.20 
(p=0.73) and 4.92 (p=0.76), respectively. Comparing V-containing vs. 
V-free regimens, no signiﬁcant difference was observed for both overall 
response (OR 0.98, CI 95% 0.83-1.15) and for progression (OR 1.06, 
CI 95% 0.92-1.21). The heterogeneity chi-square were 20.73 (p=0.07) 
and 9.03 (p=0.69), respectively. Comparing D-containing vs. D-free 
regimens, the OR for progression was 0.9313 (CI 95% 0.81-1.06; 
p=0.28); no signiﬁcant difference was observed for overall response 
(OR 0.95, CI 95% 0.77-1.17). The heterogeneity chi-square were 4.70 
(p=0.69) and 14.25 (p=0.04), respectively.
These data demonstrate a similar probability to obtain an overall re-
sponse between regimens. G containing regimens demonstrated a 14% 
reduction in the risk of an immediate progression. While P containing 
regimens were associated with a 21% increase in the risk of an im-
mediate progression. Further analyses are required to address whether 
disease control is associated with a survival beneﬁt and may therefore 
be used as a surrogate end point for survival in chemotherapy trials of 
NSCLC.
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Background: This prospective randomized, open-label, Phase III study 
(V-15-32) compared overall survival between geﬁtinib (250 mg/day) 
and docetaxel (60 mg/m2) in pretreated patients with non-small-cell 
lung cancer (NSCLC).
Methods: Patients had advanced/metastatic NSCLC and had failed 
one/two chemotherapy regimens. Stratiﬁcation factors for random-
ization were sex (female vs. male), performance status (0-1 vs. 2), 
histology (adenocarcinoma vs. others) and study site. Non-inferiority of 
the primary endpoint, overall survival, was assessed by the conﬁdence 
interval (CI) of the geﬁtinib/docetaxel hazard ratio (HR) derived from 
an unadjusted Cox proportional hazards model. Secondary endpoints 
were progression free survival (PFS), time to treatment failure (TTF), 
objective response rate (ORR), disease control rate (DCR), quality of 
life (QoL; Functional Assessment of Cancer Therapy - Lung [FACT-
L]), disease-related symptoms (FACT-L lung cancer subscale [LCS]), 
and safety. Exploratory endpoints included biomarker expression in 
tumor tissue and potential correlation with outcome.
Results: Between September 2003 and January 2006, 489 eligible 
patients (62% male, 78% adenocarcinoma, 32% never-smokers) were 
recruited from 50 institutes. Treatment arms were generally well bal-
anced for baseline demographics. Non-inferiority in overall survival 
was not achieved (HR 1.12; 95.24% CI 0.89, 1.40) according to the 
predeﬁned criterion (upper CI limit for HR <1.25), however, no signiﬁ-
cant difference in overall survival was apparent between the treatment 
groups (p=0.330). Median survival times were 11.5 (geﬁtinib) and 
14.0 (docetaxel) months. Post-study, 36% of geﬁtinib-treated patients 
received subsequent docetaxel and 40% received no other therapy apart 
from geﬁtinib; 53% of docetaxel-treated patients received subsequent 
geﬁtinib and 26% received no other therapy apart from docetaxel. 
Geﬁtinib signiﬁcantly improved ORR (22.5% vs. 12.8%; p=0.009), 
TTF (HR 0.63; 95% CI 0.51, 0.77; p<0.001) and QoL improvement 
rates (FACT-L trial outcome index 20.5% vs. 8.7%; p=0.002; FACT-L 
23.4% vs. 13.9%; p=0.023), compared with docetaxel. No signiﬁcant 
differences between treatments were seen in PFS (HR 0.90; 95% 
CI 0.72, 1.12; p=0.335), DCR (34.0% vs. 33.2%; p=0.735) or LCS 
improvement rates (22.7% vs. 20.4%; p=0.562). Adverse events (AEs) 
were consistent with those previously seen with geﬁtinib and docetaxel. 
